# A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

> **NCT07567352** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 200 (actual)

## Conditions studied

- Non-Small-Cell Lung
- ALK-positive Advanced NSCLC
- ALK-positive Non-small-cell Lung Cancer
- ALK-positive NSCLC

## Interventions

- **DRUG:** lorlatinib

## Key facts

- **NCT ID:** NCT07567352
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07567352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07567352, "A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07567352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*